AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) – Research analysts at KeyCorp cut their FY2024 earnings per share estimates for AngioDynamics in a research note issued on Thursday, January 5th. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will post earnings per share of $0.12 for the year, down from their previous estimate of $0.18. The consensus estimate for AngioDynamics' current full-year earnings is $0.01 per share. KeyCorp also issued estimates for AngioDynamics' FY2025 earnings at $0.27 EPS.
Get
AngioDynamics alerts:
A number of other equities research analysts also recently commented on the company. StockNews.com began coverage on AngioDynamics in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. Raymond James reduced their price target on shares of AngioDynamics from $25.00 to $22.00 and set a "strong-buy" rating for the company in a research report on Friday.
AngioDynamics Price Performance
Shares of ANGO stock opened at $15.17 on Monday. The firm's 50-day moving average is $13.41 and its two-hundred day moving average is $17.87. AngioDynamics has a 12 month low of $11.71 and a 12 month high of $24.87. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.16 and a quick ratio of 1.41. The company has a market capitalization of $593.27 million, a PE ratio of -18.28 and a beta of 0.66.
AngioDynamics (NASDAQ:ANGO – Get Rating) last released its earnings results on Thursday, October 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.04). AngioDynamics had a negative net margin of 9.98% and a negative return on equity of 0.14%. The firm had revenue of $81.50 million during the quarter, compared to analysts' expectations of $83.43 million. During the same quarter last year, the business earned ($0.02) EPS. The business's revenue was up 5.8% compared to the same quarter last year.
Hedge Funds Weigh In On AngioDynamics
Several hedge funds and other institutional investors have recently made changes to their positions in ANGO. Texas Permanent School Fund raised its position in shares of AngioDynamics by 2.1% in the 2nd quarter. Texas Permanent School Fund now owns 28,029 shares of the medical instruments supplier's stock valued at $542,000 after purchasing an additional 580 shares in the last quarter. US Bancorp DE boosted its holdings in shares of AngioDynamics by 36.2% in the 2nd quarter. US Bancorp DE now owns 2,562 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 681 shares during the period. Legal & General Group Plc lifted its stake in AngioDynamics by 0.9% in the second quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier's stock valued at $1,802,000 after buying an additional 851 shares during the last quarter. Brinker Capital Investments LLC grew its position in AngioDynamics by 2.3% in the 1st quarter. Brinker Capital Investments LLC now owns 41,539 shares of the medical instruments supplier's stock worth $895,000 after purchasing an additional 929 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its holdings in AngioDynamics by 16.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 6,513 shares of the medical instruments supplier's stock worth $126,000 after buying an additional 934 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company's stock.
About AngioDynamics
(Get Rating)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Recommended Stories
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
